Targeted Therapy for — Lymphoma and CLL

There are more than 60 recognised types of lymphoma, and several distinct subtypes of CLL, each driven by different proteins and gene changes. Drug classes are matched to those drivers, not to the broad label. A BTK inhibitor that works well in CLL has no established role in follicular lymphoma, where EZH2 inhibitors or PI3K inhibitors may apply instead. Your subtype is not just a name — it is the information your oncologist needs to choose the drug with the best chance of working for your specific cancer. This is also why two people with a lymphoma diagnosis may be on completely different treatment plans.

In CLL, targeted therapy is often continued for as long as it is controlling the disease and you are tolerating it, rather than for a fixed number of cycles. Some combination regimens do have a defined end point — your oncologist will explain which applies to you. In lymphoma, duration depends on the subtype and whether the drug is the first line of treatment or a later one. Ask your oncologist at the start what the intended plan looks like, so you are not left guessing month to month. The answer will be specific to your diagnosis and regimen.

BTK inhibitors can cause bruising, bleeding, joint pains, a higher risk of infection and, in some people, an irregular heartbeat called atrial fibrillation. BCL-2 inhibitors carry a risk of tumour lysis syndrome — a rapid release of substances from dying cancer cells — which is why the first doses are started carefully with blood tests and close monitoring. EZH2 inhibitors are generally well tolerated but can cause fatigue and nausea. Your team will give you a clear list of symptoms to report immediately versus those that are expected and manageable, before you take the first dose.

Yes, resistance can develop over time. In CLL, for example, a mutation in the BTK gene can emerge that prevents the drug from binding to its target. When that happens, switching to a different drug class — such as moving from a BTK inhibitor to a BCL-2 inhibitor — is often the next step, and vice versa. In lymphoma, resistance patterns depend on the subtype. Your oncologist will reassess at the point of progression to understand what has changed before recommending what comes next. A progression does not mean there are no further options.

Several targeted therapies are broken down by an enzyme called CYP3A4, and certain foods and medicines affect how active that enzyme is. Grapefruit and grapefruit juice can significantly raise blood levels of some drugs and increase the risk of side effects. Some antifungal medicines, antibiotics and heart medicines affect the same pathway. Tell your oncologist and pharmacist about every medicine, supplement and herbal or Ayurvedic preparation you take before starting targeted therapy. Never adjust your dose or stop the drug without asking your team first.

No. CAR-T is a different type of treatment where your own immune cells are taken out of your blood, modified in a specialist laboratory to recognise cancer cells, and then returned to your body. It requires highly specialised facilities and is available only at a small number of centres. Targeted therapy, by contrast, uses drugs — mostly oral tablets — that block specific proteins inside cancer cells. CION does not provide CAR-T or cell therapy. If that is being considered for you, your oncologist will refer you to a centre that offers it.